ugt1a1造句

• The " UGT1A1 " gene is located on human chromosome 2.
• UGT1A1 ) and glutathione addition reactions occur on reactive centres of the xenobiotic.
• Gilbert's syndrome is characterized by a 70 80 % reduction in the glucuronidation activity of the enzyme, ( UGT1A1 ).
• Her laboratory was the first to identify a genetic defect, in the gene UGT1A1, that leads to Crigler-Najjar syndrome.
• Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1 * 28 allele.
• Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1 * 28 allele.
• The UGT1A1 gene is part of a complex genetic variants within the UGT1A1 gene have been described, some of which confer increased, reduced or inactive enzymatic activity.
• The UGT1A1 gene is part of a complex genetic variants within the UGT1A1 gene have been described, some of which confer increased, reduced or inactive enzymatic activity.
• Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I . This is then inactivated by glucuronidation by uridine diphosphate glucoronosyltransferase 1A1 ( UGT1A1 ).
• Genetic variations within the " UGT1A1 " gene have also been associated with the development of certain variant, has also shown associations with the development of irinotecan toxicities.
• Guillemette C, De Vivo I, Hankinson SE, Haiman CA, Spiegelman D, Housman DE, Hunter DJ . Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels.
• Patients who are heterozygous or homozygous for the * 6 allele may have a higher risk for developing neutropenia and diarrhea as compared to those with the " UGT1A1 " * 1 / * 1 genotype.
• The variant of UGT1A1 in ~ 10 % of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form.
• While paracetamol ( acetaminophen ) is not metabolized by UGT1A1, it is metabolized by one of the other enzymes also deficient in some people with GS . A subset of people with GS may have an increased risk of paracetamol toxicity.
• Glucuronidation of elvitegravir is facilitated by the enzymes UGT1A1 and 3, resulting in increased blood plasma levels when taken together with strong UGT1A inhibitors such as ritonavir and other HIV protease inhibitors . ( But ritonavir also increases elvitegravir levels by inhibiting CYP3A .)
• In 2005, the FDA made changes to the labeling of irinotecan to add pharmacogenomics recommendations, such that irinotecan recipients with a homozygous ( both of the two gene copies ) polymorphism in UGT1A1 gene, to be specific, the * 28 variant, should be considered for reduced drug doses.
• However, several allelic dinucleotide repeat TA to the promoter region, resulting in A ( TA 7 ) TAA, which is called " UGT1A1 * 28 "; this common variant accounts for about 40 % of alleles in some populations, but is seen less often, around 3 % of alleles, in Southeast and East Asian people and Pacific Islanders.
• More than 100 variants of the " UGT1A1 " gene are known, designated as " UGT1A1 * n " ( where n is the general chronological order of discovery ), either of the gene itself or of its promoter region . " UGT1A1 " is associated with a TATA box promoter region; this region most commonly contains the genetic sequence A ( TA 6 ) TAA; this variant accounts for about 50 % of alleles in many populations.
• More than 100 variants of the " UGT1A1 " gene are known, designated as " UGT1A1 * n " ( where n is the general chronological order of discovery ), either of the gene itself or of its promoter region . " UGT1A1 " is associated with a TATA box promoter region; this region most commonly contains the genetic sequence A ( TA 6 ) TAA; this variant accounts for about 50 % of alleles in many populations.
• More than 100 variants of the " UGT1A1 " gene are known, designated as " UGT1A1 * n " ( where n is the general chronological order of discovery ), either of the gene itself or of its promoter region . " UGT1A1 " is associated with a TATA box promoter region; this region most commonly contains the genetic sequence A ( TA 6 ) TAA; this variant accounts for about 50 % of alleles in many populations.